Aptyx’s acquisition is reported to bring expertise in biotextiles, such as ePTFE coverings for stents and frames. (Photo: Business Wire)
The acquisition is expected to fortify Aptyx’s expertise in complex interventional products.
TEMPE, Ariz.—Aptyx, a global developer and manufacturer of complex components and devices for the life sciences, reported that it acquired the Charlotte, North Carolina facility of Medical Murray, which develops and produces catheter-based interventional products and transcatheter implants.
The acquisition will become an integral part of Aptyx Interventional Systems, fortifying the company’s interventional and implantable expertise with a rich pool of engineering talent, Aptyx said in a release.
“This marks a significant step in our growth strategy, strengthening our interventional product capabilities and end-to-end offerings, driving innovation, and delivering greater value to our OEM life science customers,” said Aptyx President and CEO Gregg Tobin, in the release. “It is a key element of our original blueprint and just the beginning of our evolution, with much more growth to follow.”
The transaction enables design and development center support and advanced manufacturing for customers and bolsters Aptyx’s expertise in catheter-based interventional products and transcatheter products, including implantable stents and frames, complex catheters, and delivery systems. It expands the company’s ISO Class 7 footprint and brings particular expertise in biotextiles, such as ePTFE coverings for stents and frames, the release stated.
According to the release, Aptyx has long been known for producing highly engineered products and for its proficiency in mission-critical molding, extrusion, coating services and equipment manufacturing, and medical device assembly.
“By combining with Medical Murray, Aptyx will now be able to provide a complete manufacturing solution for catheter-based interventional and implantable products,” the release stated.
Eric Leopold, who served as CTO of Medical Murray and leader of the Charlotte, North Carolina business, will join Aptyx post-acquisition as senior vice president.
“We’re committed to conquering technical challenges and delivering on time and cost efficient products for the structural heart, vascular, neurovascular, and other key end markets,” Leopold said in the release. “Joining Aptyx and combining our comprehensive experience in interventional markets provides the rocket fuel for long-term growth.”
Charlotte team members will become part of Aptyx. Medical Murray will continue to operate separately through its two facilities in the Chicago area.
“Aptyx Interventional Systems broadens the Aptyx footprint in the high-growth interventional market and adds competitive and high-value manufacturing and design and development capabilities,” said John Pless, co-managing partner at the private equity firm TruArc, in the release. “Continued investment is planned to further support customers in the life sciences industry, reinforcing Aptyx’s position as a trusted outsource manufacturing partner.”
Aptyx offers a broad range of specialized capabilities including engineering, molding, extrusion, coatings, and assembly, the company manufactures complex components and devices for the life sciences and other demanding industries. Headquartered in Tempe, Arizona, Aptyx has dedicated production facilities across the United States, Canada, Mexico, and China.
“The Aptyx name symbolizes the ‘aptitude meets excellence’ approach found in every aspect of the company’s operations,” the release stated.
Medical Murray has been a privately owned company since 1996, producing finished medical devices, components and subassemblies for customers ranging from startups to the largest OEMs. The company specializes in development, testing, and manufacturing of complex catheters and permanent implants for the vascular, gastrointestinal, urologic, and other interventional markets.